In association with

US HEALTHCARE AND LIFE SCIENCES CONFERENCE May 15, 2014 | New York Hilton Midtown

NEW YORK

SPEAKERS INCLUDE: J. Craig Venter, PhD Founder, CEO and Chairman J. Craig Venter Institute

Freda C. Lewis-Hall, MD Executive Vice President, Chief Medical Officer Pfizer

Lead sponsor

Luncheon sponsor

David Cordani President and CEO

Cigna

Omar Ishrak, PhD Chairman and CEO Medtronic

US HEALTHCARE AND LIFE SCIENCES CONFERENCE The third annual US Healthcare and Life Sciences Conference hosted by the Financial Times, in association with Deloitte, will take place on May 15, 2014 in New York. As healthcare reforms in the US gain traction, stakeholders are recalibrating their roles and relationships across the healthcare value chain. Chaired by Andrew Ward, Pharmaceuticals Correspondent of the Financial Times, this full-day conference brings together the industry’s leading experts and commentators to explore how reforms are reshaping market access, and the way healthcare is consumed and paid for.

PROGRAMME 9:00am OPENING REMARKS FROM THE CHAIR Andrew Ward, Pharmaceuticals Correspondent, Financial Times 9:05 am VIEW FROM THE TOP: CEO INTERVIEW Sandra Peterson, Group Worldwide Chairman, Johnson & Johnson 9:30 am US HEALTHCARE REFORM: THE NEXT CHAPTER As we prepare to enter the fourth year since the Accountable Care Act (ACA) was enacted, the reforms are gaining traction. Despite initial challenges, enrolment in the new health insurance exchanges is underway. Payers, providers and life insurance companies are experimenting with new pay-forperformance measures, and established and emerging players are realizing the potential for, and slowly building new businesses focused on bringing healthcare close to patient. In so doing, many of the stakeholders in the healthcare business are recalibrating relationships across the healthcare value chain. 2014 is a critical year in the reform process as the individual mandate kicks-in. As we cross this new threshold, what has been the impact of reform to date and the key learnings?

• How is reform impacting the ‘ecosystem’ of the healthcare and life science industry and how are stakeholder strategies evolving to take advantage of reform? • How is reform reshaping market access? • How is reform changing the way patients consume healthcare? Are they seeing improvements in their care and access? Drew Altman, PhD, President and CEO, Kaiser Family Foundation John Castellani, President and CEO, PhRMA Karen Ignagni, President and CEO, America’s Health Insurance Plans (AHIP) Stephen Rusckowski, President and CEO, Quest Diagnostics 10:30 am NETWORKING COFFEE BREAK 11:00 am KEYNOTE ADDRESS Esther Dyson, Chairman, EDventure Holdings 11:25 am HEALTHCARE EVERYWHERE: EMBRACING THE MOBILE HEALTH OPPORTUNITY Mobile healthcare, particularly when combined with other smart technologies including the cloud, social networking and the power of big data, has the potential to transform healthcare through reduced costs, extended access, changed behaviors and improved outcomes. While the reported benefits of mHealth are well known, however, many still do not know, or have been unable to capitalise on the potential and develop mobile strategies which move beyond marketing and applications to solutions and partnerships which can make a quantum impact across the continuum of care. How can the potential of mobile health be harnessed to make a real and tangible impact on health costs and transformation? • What are the impediments and how can they be addressed? How is the legal, regulatory and reimbursement regime evolving to support the expansion of mobile health and to address concerns regarding privacy and security? • What are the business models for mHealth which will provide solid returns for those who take the investment risk? How are key issues including interoperability being resolved to enable actionable knowledge and insights from accrued mobile data and to achieve scalable benefits from mHealth through wider collaboration across the health care spectrum? MODERATOR: Harry Greenspun, MD, Senior Advisor for Healthcare Transformation & Technoligy, Deloitte Center for Health Solutions SESSION KEYNOTE: Freda C. Lewis-Hall, MD, Executive Vice President, Chief Medical Officer, Pfizer Tom Gentile, President & CEO, Healthcare Systems, GE Healthcare Kerry McDermott, Senior Director, Healthcare Technology Policy, West Health Policy Center 12:25 pm CEO INSIGHTS Joe Herring, Chairman and CEO, Covance 12:45 pm LUNCHEON LUNCHEON SPONSOR: KEYNOTE ADDRESS: David Cordani, President and CEO, Cigna

2:15 pm KEYNOTE ADDRESS Derek Yach, MB ChB, Executive Director, The Vitality Institute 2:40 pm VALUE-BASED CONTRACTING AND PAYMENTS – RISING TO THE CHALLENGE Universality of access may be making headlines in the on-going debate on US healthcare reform but potentially the largest impact will come from the measures aimed at tackling the escalating cost and improving the quality of care. From Accountable Care Organizations and CER in the US to the UK’s value-based pricing, ’pay-for-performance’ reforms are making inroads and transforming healthcare around the globe. The goals of the new value system are clear but many uncertainties remain. • What is the evidence to date from the ACO pilots and value based pricing models for life science currently in place? What are the prospects that new structures will lead to a sustainable and notable disruption in the quality and cost of care? • Will the benefits outweigh the costs and risks, and is the infrastructure ready to underpin the system? • What are the value metrics and incentive structures, and are current methodologies fair? Who decides? • How are new pay-for-performance measures impacting access for life science companies? How does the US experience compare to that in Europe and elsewhere? SESSION KEYNOTE: Charles W. Sorenson, MD, President and CEO, Intermountain Healthcare Jack Bailey, Senior Vice President, Policy, Payers and Vaccines, GlaxoSmithKline Terry Hisey, Vice Chairman, US Life Sciences Leader, Deloitte David Wennberg, MD, CEO, Northern New England Accountable Care Collaborative (NNEACC) 3:40 pm NETWORKING COFFEE BREAK 4:00 pm CEO INSIGHTS Omar Ishrak, PhD, Chairman and CEO, Medtronic 4:25 pm CLOSING KEYNOTE J. Craig Venter, PhD, Founder, CEO and Chairman, J. Craig Venter Institute 4:55 pm CLOSING REMARKS FROM THE CHAIR Andrew Ward, Pharmaceuticals Correspondent, Financial Times 5:05 pm END OF CONFERENCE

For the latest programme and speaker updates, visit

www.ft-live.com/USHC2014

WHO SHOULD ATTEND: This event is for: CEOs, CFOs, CIOs, Chief Medical Officers, Chief Strategy Officers, Heads of R&D, Emerging Markets, Consumer Health, Government Relations, Pricing, Regulation, Market Access, etc. and other senior-level executives in the following sectors: • • • • • •

Pharmaceuticals, Biotechnology, Generic and Specialty Pharmaceutical companies Medical Devices and Diagnostics Investment (Fund Managers, Venture Capitalists, Private Equity firms, Investment Bankers, IP Groups) Legal Counsel Healthcare IT (Patient records, data, mobile healthcare applications, social media) Regulation

SUPPORTING PARTNERS

US HEALTHCARE AND LIFE SCIENCES CONFERENCE SUMMIT PRICING Fee

Rate Early rate II (expires Mar 28)

Standard Rate

Standard Registration

$1395

$1695

Non-profit/Government

$695

$795

HOW TO REGISTER

VENUE INFORMATION

www.ft-live.com/ushc2014

INFORMATION For registration, discounts and general attendance information: Melissa Papasidero E

[email protected]

T

+1 917-551-5106

For sponsorship enquiries: Tim Powell E

[email protected]

T

+1 917-551-5097

@FTLive #FTUSHC

New York Hilton Midtown 1335 Avenue of the Americas New York, NY 10019 Phone: +1-212-586-7000

facebook.com/FinancialTimesLive

on.ft.com/linkedin